Chronic intermittent hypoxia contributes to non-alcoholic steatohepatitis progression in patients with obesity

被引:13
|
作者
Fu, Yuzhe [1 ]
Zhang, Ningjing [2 ]
Tang, Wenjuan [2 ]
Bi, Yan [2 ]
Zhu, Dalong [2 ]
Chu, Xuehui [3 ]
Shan, Xiaodong [3 ]
Shen, Yuanyuan [1 ]
Sun, Xitai [3 ]
Feng, Wenhuan [1 ]
机构
[1] Nanjing Med Univ, Clin Coll, Nanjing Drum Tower Hosp, Dept Endocrinol, Nanjing, Peoples R China
[2] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Endocrinol, Nanjing, Peoples R China
[3] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Gen Surg, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obstructive sleep apnea; Obesity; Chronic intermittent hypoxia; Liver biopsy; Polysomnography; Apnea-hypopnea index; Non-alcoholic fatty liver disease activity score; Non-alcoholic steatohepatitis activity grade; FATTY LIVER-DISEASE; OBSTRUCTIVE SLEEP-APNEA; SCORING SYSTEM; EPIDEMIOLOGY; ASSOCIATION; THERAPY; MODEL;
D O I
10.1007/s12072-022-10347-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and purpose The association between the severity of obstructive sleep apnea (OSA) and non-alcoholic fatty liver disease (NAFLD) in patients with obesity remains unclear. We conducted this study to determine the effects of OSA on the severity of NAFLD in individuals with obesity and its link to the development of non-alcoholic steatohepatitis (NASH). Methods Patients were subjected to standard polysomnography up to 1 week before undergoing bariatric surgery, during which liver biopsy specimens were obtained. The apnea-hypopnea index (AHI) obtained by polysomnography was used to determine the severity of OSA. Results In total, 183 patients with obesity and biopsy-confirmed NAFLD were included; 49 (27%) had NASH. Patients with NASH had higher AHIs (p = 0.014) and oxygen desaturation indices (p = 0.031), more frequent OSA (p = 0.001), and lower minimum oxygen saturation (p = 0.035). The severity of OSA was directly correlated with the NAFLD activity score (p < 0.001), NASH activity grade (p < 0.001), semi-quantitative indices of lobular inflammation (p = 0.001), and hepatocyte ballooning (p = 0.006). The odds ratios (95% confidence intervals) for NASH and severe NASH (activity grade >= 3) associated with moderate-to-severe OSA were 3.85 (1.35-10.94; p < 0.05) and 5.02 (1.66-15.18; p < 0.01), respectively, after adjusting for sex, age, body mass index, waist circumference, insulin resistance values, and metabolic syndrome. Conclusions Chronic intermittent hypoxia caused by OSA may aggravate NAFLD and lead to a higher risk of NASH in patients with obesity.
引用
收藏
页码:824 / 834
页数:11
相关论文
共 50 条
  • [1] Chronic intermittent hypoxia contributes to non-alcoholic steatohepatitis progression in patients with obesity
    Yuzhe Fu
    Ningjing Zhang
    Wenjuan Tang
    Yan Bi
    Dalong Zhu
    Xuehui Chu
    Xiaodong Shan
    Yuanyuan Shen
    Xitai Sun
    Wenhuan Feng
    Hepatology International, 2022, 16 : 824 - 834
  • [2] Chronic intermittent hypoxia promotes the development of experimental non-alcoholic steatohepatitis by modulating Treg/Th17 differentiation
    Liu, Jiang
    Li, Weiping
    Zhu, Weihua
    He, Weimei
    Zhao, Hui
    Xiang, Yu
    Liu, Chunyan
    Wu, Wei
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (12) : 1200 - 1210
  • [3] Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity
    Meneses, Diego
    Olveira, Antonio
    Corripio, Ramon
    Mendez, Maria del Carmen
    Romero, Miriam
    Calvo-Vinuelas, Isabel
    Herranz, Lucrecia
    Vicent, David
    de-Cos-Blanco, Ana Isabel
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2022, 69 (03): : 178 - 188
  • [4] Diagnostics of progression of liver fibrosis in patients with non-alcoholic steatohepatitis combined with obesity and chronic calculous cholecystitis
    Filippova, A. Yu
    MEDICNI PERSPEKTIVI, 2020, 25 (01): : 65 - 73
  • [5] Therapeutic approaches for non-alcoholic steatohepatitis
    Van Gaal, Luc F.
    Mertens, Jonathan
    Francque, Sven
    De Block, Christophe
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2021, 12
  • [6] Alcoholic and non-alcoholic steatohepatitis
    Neuman, Manuela G.
    French, Samuel W.
    French, Barbara A.
    Seitz, Helmut K.
    Cohen, Lawrence B.
    Mueller, Sebastian
    Osna, Natalia A.
    Kharbanda, Kusum K.
    Seth, Devanshi
    Bautista, Abraham
    Thompson, Kyle J.
    McKillop, Iain H.
    Kirpich, Irina A.
    McClain, Craig J.
    Bataller, Ramon
    Nanau, Radu M.
    Voiculescu, Mihai
    Opris, Mihai
    Shen, Hong
    Tillman, Brittany
    Li, Jun
    Liu, Hui
    Thomes, Paul G.
    Ganesan, Murali
    Malnick, Steve
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2014, 97 (03) : 492 - 510
  • [7] Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
    Hartmann, Phillipp
    Duan, Yi
    Miyamoto, Yukiko
    Demir, Munevver
    Lang, Sonja
    Hasa, Elda
    Stern, Patrick
    Yamashita, Dennis
    Conrad, Mary
    Eckmann, Lars
    Schnabl, Bernd
    HEPATOLOGY INTERNATIONAL, 2022, 16 (02) : 359 - 370
  • [8] Filamin A is overexpressed in non-alcoholic steatohepatitis and contributes to the progression of inflammation and fibrosis
    Lu, Ying
    Wang, Mengzhu
    Zhao, Manyu
    Zhang, Qianru
    Qian, Rui
    Hu, Zan
    Ke, Qi
    Yu, Lin
    Wang, Liqun
    Lai, Qinhuai
    Liu, Zhenmi
    Jiang, Xia
    Zhang, Ben
    Yang, Jinliang
    Yao, Yuqin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 653 : 93 - 101
  • [9] Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice
    Lee, Samuel M.
    Muratalla, Jose
    Karimi, Saman
    Diaz-Ruiz, Alberto
    Frutos, Maria Dolores
    Guzman, Grace
    Ramos-Molina, Bruno
    Cordoba-Chacon, Jose
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (02)
  • [10] Emerging drugs for non-alcoholic steatohepatitis
    Tomeno, Wataru
    Yoneda, Masato
    Imajo, Kento
    Ogawa, Yuji
    Kessoku, Takaomi
    Saito, Satoru
    Eguchi, Yuichiro
    Nakajima, Atsushi
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (03) : 279 - 290